
AstraZeneca's osimertinib, sold as Tagrisso, has demonstrated significant benefits for patients with a specific type of non-small cell lung cancer. In a clinical trial with over 680 participants at the early stages of the disease, those who took osimertinib had a 51% lower risk of death than those who received a placebo. After five years, 88% of patients on osimertinib were still alive, while the placebo group had a survival rate of 78%.
Like
Save
Share